AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AbbVie is set to acquire Apogee Therapeutics in a deal valued at $10.9 billion. The acquisition is framed as a strategic effort to enhance the company's research and presence within the immunology sector.
Coverage from Fierce Biotech, The Wall Street Journal, CNBC, and the AbbVie News Center emphasizes the transaction's focus on bolstering the firm's growth in immunology. Reports highlight the inclusion of a specific eczema drug candidate as a primary component of the deal.
Future developments will depend on the finalization of the acquisition process. Coverage does not yet specify the anticipated closing date for the transaction or the specific regulatory hurdles that may remain.
Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 140d ago.
Quick answers
What is the total value of the acquisition?
The acquisition of Apogee Therapeutics by AbbVie is valued at $10.9 billion.
What is the strategic goal of the purchase?
AbbVie intends to deepen its immunology portfolio, specifically acquiring an eczema drug prospect.
Which organizations are involved?
The companies involved in this transaction are AbbVie and Apogee Therapeutics.
Coverage (7)
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 140d ago
- AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion Yahoo Finance · 140d ago
- AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · 140d ago
- AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect Fierce Biotech · 140d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 140d ago
- AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push CNBC · 140d ago
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News Center · 140d ago
Topics
Related trends
Children’s Place Files for Bankruptcy With Plans to Sell Assets
The Children's Place files for bankruptcy and plans asset sales as loans run dry.
Restaurant 'admin' fees spark backlash as diners question what they're paying for
A diner's viral post showing an unexpected 'admin fee' on a $30.86 restaurant bill has sparked a backlash against hidden surcharges.
Nvidia's stock slides as questions swirl around Jensen Huang's future as CEO
Nvidia shares fell 5% Monday after the board opened an investigation into CEO Jensen Huang's admitted affair with a woman identified as Alice Huang, who U.S. intelligence reportedly believes was gathering information for China.
Mitsui Chemicals to Acquire JSR With Development Bank of Japan for $8.8 Billion
Mitsui Chemicals has agreed to acquire chip materials maker JSR for 1.84 trillion yen, about $11.6 billion, with Japan's Development Bank of Japan taking a stake.
Morning Bid: Fragile calm after AI whiplash
Markets steady after a sharp AI-driven tech selloff pushed the Nasdaq into correction territory, leaving investors assessing whether the pullback has run its course.
Nvidia opens investigation after reports CEO Jensen Huang was targeted by Chinese intelligence
Nvidia opened an independent investigation after reports its CEO, Jensen Huang, was targeted by Chinese intelligence.